Intelligence Feed event · Macro · 2026-09-21

    Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks

    Question

    Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks

    Direct answer

    Ionis Pharmaceuticals is under sustained market pressure, with equity values falling more than 40% following setbacks in its late-stage clinical pipeline. Disappointments in the pelacarsen and eplontersen development programs have compounded ongoing operating losses. Despite the clinical headwinds, sell-side price targets average $83.82, underpinned by partner royalties and ongoing development across the broader antisense oligonucleotide portfolio.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-21
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks”, revision 1, evidence through 2026-09-21. https://marketontology.com/market-events/2026-09-21/ionis-pharmaceuticals-trades-down-40-following-late-stage-clinical-setbacks-df2a66

    MACRO
    Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks
    Ionis Pharmaceuticals is under sustained market pressure, with equity values falling more than 40% following setbacks in its late-stage clinical pipeline. Disappointments in the pelacarsen and eplontersen development programs have compounded ongoing operating losses. Despite the clinical headwinds, sell-side price targets average $83.82, underpinned by partner royalties and ongoing development across the broader antisense oligonucleotide portfolio.
    IONSAZNBIIB
    Impact
    67
    SEP 21
    SIG
    85%
    IONSAZNBIIB
    Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks
    Ionis Pharmaceuticals is under sustained market pressure, with equity values falling more than 40% following setbacks in its late-stage clinical pipeline. Disappointments in the pelacarsen and eplontersen development programs have compounded ongoing operating losses. Despite the clinical headwinds, sell-side price targets average $83.82, underpinned by partner royalties and ongoing development across the broader antisense oligonucleotide portfolio.
    → Pipeline clinical setbacks across pelacarsen and eplontersen reduce discounted long-term milestone cash flows, compressing IONS market capitalization.
    Impact
    Ionis Pharmaceuticals is under sustained market pressure, with equity values falling more than 40% following setbacks in its late-stage clinical pipeline. Disappointments in the pelacarsen and eplontersen development programs have compounded ongoing operating losses. Despite the clinical headwinds, sell-side price targets average $83.82, underpinned by partner royalties and ongoing development across the broader antisense oligonucleotide portfolio.
    Affected
    IONSAZNBIIB
    Transmission
    Pipeline clinical setbacks across pelacarsen and eplontersen reduce discounted long-term milestone cash flows, compressing IONS market capitalization.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    IONSclinical pipeline NPV write-down and milestone cash flow contractionDown1-3mStock dropped over 40% year-to-date on pelacarsen and eplontersen pipeline failures.
    AZNcommercial partnership milestone timeline adjustmentsMixed1-4wAstraZeneca collaborates on Ionis clinical pipeline assets.
    BIIBbiotech partner sentiment and ASO technology platform read-acrossMixed1-4wBiogen maintains active collaboration on Ionis antisense oligonucleotide technology.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    IONSDowndisagreed44.90 2026-09-21+1.89%+1.49%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month